Skip to main content

Markers of Prostate Cancer: The Role of Circulating Tumor Markers in the Management of Bone Metastases

  • 1291 Accesses

Abstract

The present chapter concerns the role of circulating tumor markers in the management of bone metastases in patients with prostate cancer. We first discuss the contemporary notion of tumor markers from a general point of view. We focus on some specific characteristics of prostate-specific antigen (PSA), showing why it is the sole circulating tumor marker presently recommended in the follow-up of patients – with or without metastases – treated with curative intents for a primary prostate cancer. The role of PSA in the different clinical settings in which the marker may be used is then discussed. The position of the most recent clinical practice guidelines is examined, and recommendations concerning PSA are presented and discussed with reference to key clinical scenarios. We considered the initial assessment of the risk of developing bone metastases, the early detection of relapse during the follow-up, and the management of the relapse; this latter issue is discussed considering separately patients with biochemical relapse and those with manifest clinical metastases.

Keywords

  • Prostate Cancer
  • Bone Metastasis
  • Radical Prostatectomy
  • Androgen Deprivation Therapy
  • Biochemical Recurrence

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-319-42327-2_4
  • Chapter length: 13 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   109.00
Price excludes VAT (USA)
  • ISBN: 978-3-319-42327-2
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   149.99
Price excludes VAT (USA)
Hardcover Book
USD   149.99
Price excludes VAT (USA)

References

  1. Khleif SN, Doroshow JH, Hait WN (2010) AACR-FDA-NCI Cancer Biomarkers Collaborative AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res 16(13):3299–3318

    CAS  CrossRef  PubMed  Google Scholar 

  2. Diamandis EP (2014) Present and future of cancer biomarkers. Clin Chem Lab Med 52(6):791–794

    CAS  PubMed  Google Scholar 

  3. Akobeng AK (2007) Understanding diagnostic tests 2: likelihood ratios, pre- and post-test probabilities and their use in clinical practice. Acta Paediatr 96(4):487–491

    CrossRef  PubMed  Google Scholar 

  4. Sandblom G, Ladjevardi S, Garmo H, Varenhorst E (2008) The impact of prostate-specific antigen level at diagnosis on the relative survival of 28,531 men with localized carcinoma of the prostate. Cancer 112(4):813–819

    CrossRef  PubMed  Google Scholar 

  5. Roehrborn CG, McConnell J, Bonilla J, Rosenblatt S, Hudson PB, Malek GH, Schellhammer PF, Bruskewitz R, Matsumoto AM, Harrison LH, Fuselier HA, Walsh P, Roy J, Andriole G, Resnick M, Waldstreicher J (2000) Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 163(1):13–20.

    Google Scholar 

  6. Lepor A, Catalona WJ, Loeb S (2016) The prostate health index: its utility in prostate cancer detection. v Urol Clin North Am 43(1):1–6

    Google Scholar 

  7. Yang Z, Yu L, Wang Z (2016) PCA3 and TMPRSS2-ERG gene fusions as diagnostic biomarkers for prostate cancer. Chin J Cancer Res 28(1):65–71

    PubMed  PubMed Central  Google Scholar 

  8. Freedland SJ, Moul JW (2007) Prostate specific antigen recurrence after definitive therapy. J Urol 177:1985–1991

    CrossRef  PubMed  Google Scholar 

  9. Briganti A, Suardi N, Gallina A, Abdollah F, Novara G, Ficarra V, Montorsi F (2014) Predicting the risk of bone metastasis in prostate cancer. Cancer Treat Rev 40:3–11

    CAS  CrossRef  PubMed  Google Scholar 

  10. D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969–974

    CrossRef  PubMed  Google Scholar 

  11. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, Carroll PR (2005) The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 173:1938–1942

    CrossRef  PubMed  PubMed Central  Google Scholar 

  12. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT (1998) A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90(10):766–771

    CAS  CrossRef  PubMed  Google Scholar 

  13. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD (1997) Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277:1445–1451

    CAS  CrossRef  PubMed  Google Scholar 

  14. Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW (2008) An updated catalog of prostate cancer predictive tools. Cancer 113:3075–3099

    CrossRef  PubMed  Google Scholar 

  15. Gion M, Trevisiol C, Pregno S, Fabricio ASC (2010) Guida all’uso clinico dei biomarcatori in oncologia. Biomedia, Milano

    Google Scholar 

  16. Chin JL, Srigley J, Mayhew LA, Rumble RB, Crossley C, Hunter A, Fleshner N, Bora B, McLeod R, McNair S, Langer B, Evans A (2010) Guideline for optimization of surgical and pathological quality performance for radical prostatectomy in prostate cancer management: evidentiary base. Can Urol Assoc J 4(1):13–25

    CrossRef  PubMed  PubMed Central  Google Scholar 

  17. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D’Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen CM; AUA Prostate Cancer Clinical Guideline Update Panel (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177(6):2106–2131

    Google Scholar 

  18. Horwich A, Parker C, de Reijke T, Kataja V; ESMO Guidelines Working Group (2013) Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24(Suppl6):vi106–114

    Google Scholar 

  19. National Collaborating Centre for Cancer (2014) Prostate cancer: diagnosis and treatment. National Institute for Health and Care Excellence, London

    Google Scholar 

  20. Mottet N, Bellmunt J, Briers E, van den Bergh RCN, Bolla M, van Casteren NJ, Cornford P, Culine S, Joniau S, Lam T, Mason MD, Matveev V, van der Poel H, van der Kwast TH, Rouvière O, Wiegel T (2015) Guidelines on prostate cancer. European Association of Urology, Arnhem

    Google Scholar 

  21. National Comprehensive Cancer Network (NCCN) (2015) Clinical practice guidelines in oncology. Prostate cancer. Washington, PA: National Comprehensive Cancer Network

    Google Scholar 

  22. Hoskin PJ, Colombo A, Henry A, Niehoff P, Paulsen Hellebust T, Siebert FA, Kovacs G (2013) GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiother Oncol 107(3):325–332

    CrossRef  PubMed  Google Scholar 

  23. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P; American Urological Association (2013) Prostate specific antigen best practice statement: 2009 update. J Urol 189(1 Suppl):S2–S11

    Google Scholar 

  24. Alberta Provincial Genitourinary Tumour Team (2013) Prostate cancer. Cancer Control Alberta, Edmonton

    Google Scholar 

  25. Associazione Italiana di Oncologia Medica (2014) Linee guida carcinoma della prostata. AIOM, Milano

    Google Scholar 

  26. Banefelt J, Liede A, Mesterton J, Stålhammar J, Hernandez RK, Sobocki P, Persson BE (2014) Survival and clinical metastases among prostate cancer patients treated with androgen deprivation therapy in Sweden. Cancer Epidemiol 38:442–447

    CAS  CrossRef  PubMed  Google Scholar 

  27. Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT (2010) Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999–2007). J Urol 184:162–167

    CrossRef  PubMed  Google Scholar 

  28. Nguyen-Nielsen M, Liede A, Maegbaek ML, Borre M, Harving N, Hernandez RK, Toft Sørensen H, Ehrenstein V (2015) Survival and PSA-markers for mortality and metastasis in nonmetastatic prostate cancer treated with androgen deprivation therapy. Cancer Epidemiol 39:623–632

    CrossRef  PubMed  Google Scholar 

  29. Hess KR, Varadhachary GR, Taylor SH et al (2006) Metastatic patterns in adenocarcinoma. Cancer 106:1624–1633

    CrossRef  PubMed  Google Scholar 

  30. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, Partin AW (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294:433–439

    CAS  CrossRef  PubMed  Google Scholar 

  31. Pound CR, Partin AW, Eisenberger MA et al (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591–1597

    CAS  CrossRef  PubMed  Google Scholar 

  32. Crawford ED, Stone NN, Yu EY, Koo PJ, Freedland SJ, Slovin SF, Gomella LG, Berger ER, Keane TE, Sieber P, Shore ND, Petrylak DP; Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR) Group (2014) Challenges and recommendations for early identification of metastatic disease in prostate cancer. Urology 83:664–669

    Google Scholar 

  33. Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR et al (2006) Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer 106(8):1708–1714

    CrossRef  PubMed  Google Scholar 

  34. Sharifi N, Gulley JL, Dahut WL (2005) Androgen deprivation therapy for prostate cancer. JAMA 294(2):238–244

    CAS  CrossRef  PubMed  Google Scholar 

  35. Kirby M, Hirst C, Crawford ED (2011) Characterising the castration resistant prostate cancer population: a systematic review. Int J Clin Pract 65:1180–1192

    CAS  CrossRef  PubMed  Google Scholar 

  36. Zagars GK, Pollack A (1993) The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer. Cancer 72:832–834

    CAS  CrossRef  PubMed  Google Scholar 

  37. Freedland SJ, Rumble RB, Finelli A, Chen RC, Slovin S, Stein MN, Mendelson DS, Wackett C, Sandler HM (2014) Adjuvant and salvage radiotherapy after prostatectomy: American Society of Clinical Oncology clinical practice guideline endorsement. J Clin Oncol 32(34):3892–3898

    CrossRef  PubMed  Google Scholar 

  38. Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, Klein E, Michalski J, Roach M, Sartor O, Wolf JS Jr, Faraday MM (2013) Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol 190(2):441–449

    CrossRef  PubMed  Google Scholar 

  39. Izawa JI, Klotz L, Siemens DR, Kassouf W, So A, Jordan J, Chetner M, Iansavichene AE (2011) Prostate cancer screening: Canadian guidelines 2011. Can Urol Assoc J 5(4):235–240

    CrossRef  PubMed  PubMed Central  Google Scholar 

  40. Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H (2006) Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65(4):965–974

    CrossRef  PubMed  Google Scholar 

  41. Skolarus TA, Wolf AM, Erb NL, Brooks DD, Rivers BM, Underwood W 3rd, Salner AL, Zelefsky MJ, Aragon-Ching JB, Slovin SF, Wittmann DA, Hoyt MA, Sinibaldi VJ, Chodak G, Pratt-Chapman ML, Cowens-Alvarado RL (2014) American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin 64(4):225–249

    CrossRef  PubMed  Google Scholar 

  42. Climent MA, Piulats JM, Sánchez-Hernández A, Arranz JÁ, Cassinello J, García-Donas J, González del Alba A, León-Mateos L, Mellado B, Méndez-Vidal MJ, Pérez-Valderrama B; Spanish Oncology Genitourinary Group (2012) Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer. Crit Rev Oncol Hematol 83(3):341–352

    Google Scholar 

  43. Gillessen S, Omlin A, Attard G, de Bono JS, Efstathiou E, Fizazi K, Halabi S, Nelson PS, Sartor O, Smith MR, Soule HR, Akaza H, Beer TM, Beltran H, Chinnaiyan AM, Daugaard G, Davis ID, De Santis M, Drake CG, Eeles RA, Fanti S, Gleave ME, Heidenreich A, Hussain M, James ND, Lecouvet FE, Logothetis CJ, Mastris K, Nilsson S, Oh WK, Olmos D, Padhani AR, Parker C, Rubin MA, Schalken JA, Scher HI, Sella A, Shore ND, Small EJ, Sternberg CN, Suzuki H, Sweeney CJ, Tannock IF, Tombal B (2015) Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 26(8):1589–1604

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  44. Freedland SJ, Howard LE, Hanyok BT, Kadiyala VK, Kuang JY, Whitney CA, Wilks FR, Kane CJ, Terris MK, Amling CL, Cooperberg MR, Aronson WJ, Moreira DM (2016) Validation of a bone scan positivity risk table in non-metastatic castration-resistant prostate cancer. BJU Int

    Google Scholar 

  45. Moreira DM, Howard LE, Sourbeer KN et al (2015) Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 18:333–337

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  46. Arlen PM, Bianco F, Dahut WL, D’Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O (2008) Prostate specific antigen working group guidelines on prostate specific antigen doubling time. J Urol 179:2181–2186

    CrossRef  PubMed  PubMed Central  Google Scholar 

  47. Daskivich TJ, Regan MM, Oh WK (2006) Prostate specific antigen doubling time calculation: not as easy as 1, 2, 4. J Urol 176:1927–1937

    CrossRef  PubMed  Google Scholar 

  48. Scher HI, Eisenberger M, D’Amico AV, Halabi S, Small EJ, Morris M, Kattan MW, Roach M, Kantoff P, Pienta KJ, Carducci MA, Agus D, Slovin SF, Heller G, Kelly WK, Lange PH, Petrylak D, Berg W, Higano C, Wilding G, Moul JW, Partin AN, Logothetis C, Soule HR (2004) Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 22(3):537–556

    CrossRef  PubMed  Google Scholar 

  49. Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, Garrels K, Hotte S, Kattan MW, Raghavan D, Saad F, Taplin ME, Walker-Dilks C, Williams J, Winquist E, Bennett CL, Wootton T, Rumble RB, Dusetzina SB, Virgo KS (2014) Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol 32(30):3436–3448

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  50. Cookson MS, Lowrance WT, Murad MH, Kibel AS; American Urological Association (2015) Castration-resistant prostate cancer: AUA guideline amendment. J Urol 193(2):491–499

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Massimo Gion .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Gion, M., Trevisiol, C., Rainato, G., Fabricio, A.S.C. (2017). Markers of Prostate Cancer: The Role of Circulating Tumor Markers in the Management of Bone Metastases. In: Bertoldo, F., Boccardo, F., Bombardieri, E., Evangelista, L., Valdagni, R. (eds) Bone Metastases from Prostate Cancer . Springer, Cham. https://doi.org/10.1007/978-3-319-42327-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42327-2_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42326-5

  • Online ISBN: 978-3-319-42327-2

  • eBook Packages: MedicineMedicine (R0)